The goal of the Accelerating Medicines Partnership® is to bring together the resources of the National Institutes of Health (NIH) and the private sector to improve our understanding of disease pathways, facilitate better selection of targets for treatment, and identify platforms and processes to accelerate therapies to patients.
AMP Alzheimer’s Disease 2.0
The Accelerating Medicines Partnership® (AMP®) Program Alzheimer’s disease (AMP AD 2.0) is a precompetitive public-private partnership that will enable precision medicine research for Alzheimer’s disease through deep and longitudinal molecular analyses across diverse populations to provide insights that will accelerate the development of therapies for Alzheimer’s disease.
AMP® Bespoke Gene Therapy Consortium (BGTC)
The Accelerating Medicines Partnership® (AMP®) Program Bespoke Gene Therapy Consortium (AMP BGTC) brings together partners from the public, private, and non-profit sectors to foster development of gene therapies intended to treat rare genetic diseases, which affect populations too small for viable commercial development.
AMP Heart Failure
The Accelerating Medicines Partnership® Heart Failure Program (AMP® HF) is focused on a major unmet need in cardiovascular health. AMP HF brings together partners from the public, private, and nonprofit sectors to investigate the syndrome of heart failure with preserved ejection fraction (HFpEF), which continues to stymie researchers and clinicians.
The Accelerating Medicines Partnership® (AMP®) Program Schizophrenia (AMP SCZ) is the first neuropsychiatric project of the landmark AMP program, managed by the Foundation for the National Institutes of Health. This major public-private partnership between NIH’s National Institute of Mental Health (NIMH) and private partner organizations from the industry and nonprofit sectors addresses the critical need for more effective treatments for individuals with schizophrenia and related mental health conditions.
AMP Autoimmune & Immune-Mediated Diseases
The Accelerating Medicines Partnership® (AMP®) Program Autoimmune and Immune-Mediated Diseases (AMP AIM) is a precompetitive partnership that brings together the resources of 20 partner organizations spanning the public, private, and not-for-profit sectors. Managed by the FNIH, the project builds on the success of AMP RA/SLE, which pioneered a transformational approach to dissect how these diseases occur at the individual cell level.
AMP Common Metabolic Disorders
The Accelerating Medicines Partnership® (AMP®) Program in Common Metabolic Diseases (AMP CMD) is a collaborative partnership among government and private-sector partners that harnesses their collective capabilities, scale, and resources to therapeutically address multiple metabolic diseases that share common pathogenic drivers and overlapping molecular pathways and make them available in a precompetitive space.
AMP Parkinson’s Disease
The Accelerating Medicines Partnership® (AMP®) Program Parkinson’s disease (AMP PD) is a public-private partnership among NIH and private sector organizations. Managed by the Foundation for the NIH, this partnership aims to identify and validate biomarkers for diagnostic, prognostic and/or disease progression biomarkers for PD and, to provide new tools for use in clinical trials thereby accelerating the development of novel therapies.